The University of Adelaide, South Australia, Australia.
The Adelaide Clinic, Ramsay Health Care (SA) Mental Health Services, South Australia, Australia; Discipline of Psychiatry, School of Medicine, The University of Adelaide, South Australia, Australia.
J Affect Disord. 2019 Jun 1;252:435-439. doi: 10.1016/j.jad.2019.03.085. Epub 2019 Mar 30.
The presence of comorbid anxiety is generally associated with poorer treatment outcomes in people with depression. Repetitive transcranial magnetic stimulation (rTMS) has been shown to be effective for treatment resistant depression, but there has been little research examining rTMS in depressed patients with comorbid anxiety disorders. This study aimed to investigate the efficacy of rTMS in patients with treatment resistant Major Depressive Disorder (MDD) and comorbid anxiety disorders.
This study included 248 patients with treatment resistant MDD who were treated with rTMS. Of these, 172 patients had one or more comorbid anxiety disorders, so their outcomes were compared with patients who did not have comorbid anxiety.
Patients both with and without comorbid anxiety disorders showed improvement in depression ratings after rTMS treatment, with no significant difference in remission rates between groups. In those with comorbid anxiety disorders, 23.3% met criteria for remission and 39.5% met response criteria. For each anxiety disorder diagnosis, there was a significant reduction in HAM-A, HAM-D21, MADRS and ZUNG scores (p = <0.001 for all).
This was not a sham-controlled study, so placebo response rates are not known. Patients were referred by private psychiatrists so are not representative of all patients with depression.
Our study indicates that rTMS is an effective treatment for Major Depressive Disorder in people who have comorbid anxiety disorders.
焦虑共病通常与抑郁症患者的治疗效果较差相关。重复经颅磁刺激(rTMS)已被证明对治疗抵抗性抑郁症有效,但针对伴有焦虑障碍的抑郁患者的 rTMS 研究甚少。本研究旨在探讨 rTMS 对伴有焦虑障碍的治疗抵抗性重度抑郁症(MDD)患者的疗效。
本研究纳入了 248 例接受 rTMS 治疗的治疗抵抗性 MDD 患者。其中,172 例患者患有一种或多种共病焦虑障碍,因此将他们的结局与无共病焦虑障碍的患者进行比较。
伴有和不伴有共病焦虑障碍的患者在 rTMS 治疗后抑郁评分均有改善,两组间缓解率无显著差异。在伴有焦虑障碍的患者中,23.3%符合缓解标准,39.5%符合应答标准。对于每种焦虑障碍诊断,HAM-A、HAM-D21、MADRS 和 ZUNG 评分均显著降低(所有 p 值均<0.001)。
这不是假刺激对照研究,因此不知道安慰剂的缓解率。患者由私人精神科医生转诊,因此不能代表所有抑郁症患者。
本研究表明,rTMS 是治疗伴有焦虑障碍的重度抑郁症患者的有效方法。